Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) was $13.45 for the day, up 7.60% from the previous closing price of $12.5. In other words, the price has increased by $7.60 from its previous closing price. On the day, 1.97 million shares were traded. PHAT stock price reached its highest trading level at $13.85 during the session, while it also had its lowest trading level at $12.26.
Ratios:
Our analysis of PHAT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.35 and its Current Ratio is at 2.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 14, 2025, initiated with a Overweight rating and assigned the stock a target price of $23.
On May 03, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $24.
Needham reiterated its Buy rating for the stock on January 05, 2024, while the target price for the stock was revised from $23 to $26.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 05 ’25 when Breedlove Robert Charles sold 461 shares for $12.09 per share. The transaction valued at 5,573 led to the insider holds 47,931 shares of the business.
Breedlove Robert Charles sold 1,692 shares of PHAT for $14,152 on Jul 16 ’25. The Principal Accounting Officer now owns 48,392 shares after completing the transaction at $8.36 per share. On May 21 ’25, another insider, Topper James N, who serves as the Director of the company, bought 3,780 shares for $3.86 each. As a result, the insider paid 14,609 and bolstered with 59,403 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PHAT now has a Market Capitalization of 954192896 and an Enterprise Value of 1379118592. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.37. Its current Enterprise Value per Revenue stands at 12.093 whereas that against EBITDA is -5.141.
Stock Price History:
The Beta on a monthly basis for PHAT is 0.45, which has changed by -0.23029554 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, PHAT has reached a high of $19.50, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 17.07%, while the 200-Day Moving Average is calculated to be 76.52%.
Shares Statistics:
PHAT traded an average of 1.18M shares per day over the past three months and 1497510 shares per day over the past ten days. A total of 70.10M shares are outstanding, with a floating share count of 39.79M. Insiders hold about 43.91% of the company’s shares, while institutions hold 46.63% stake in the company. Shares short for PHAT as of 1759190400 were 13199013 with a Short Ratio of 11.18, compared to 1756425600 on 13172777. Therefore, it implies a Short% of Shares Outstanding of 13199013 and a Short% of Float of 30.719997999999997.
Earnings Estimates
A comprehensive evaluation of Phathom Pharmaceuticals Inc (PHAT) is underway, with the input of 4.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.17 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$2.3 and -$3.32 for the fiscal current year, implying an average EPS of -$2.63. EPS for the following year is -$0.11, with 4.0 analysts recommending between $0.93 and -$1.16.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 8 analysts. It ranges from a high estimate of $49.38M to a low estimate of $45.4M. As of. The current estimate, Phathom Pharmaceuticals Inc’s year-ago sales were $16.35MFor the next quarter, 8 analysts are estimating revenue of $55.19M. There is a high estimate of $58.1M for the next quarter, whereas the lowest estimate is $51M.
A total of 8 analysts have provided revenue estimates for PHAT’s current fiscal year. The highest revenue estimate was $173.47M, while the lowest revenue estimate was $165M, resulting in an average revenue estimate of $170.09M. In the same quarter a year ago, actual revenue was $55.25MBased on 7 analysts’ estimates, the company’s revenue will be $323.42M in the next fiscal year. The high estimate is $359.47M and the low estimate is $280M.
